Q2 EPS Estimates for Align Technology Cut by Leerink Partnrs

Align Technology, Inc. (NASDAQ:ALGN) – Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Align Technology in a report issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the medical equipment provider will post earnings of $1.90 per share for the quarter, down from their prior estimate of $2.09. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.17 EPS, FY2025 earnings at $7.46 EPS, FY2026 earnings at $8.75 EPS and FY2027 earnings at $10.20 EPS.

Several other equities analysts have also issued reports on ALGN. Evercore ISI boosted their price target on Align Technology from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Morgan Stanley reduced their target price on Align Technology from $280.00 to $272.00 and set an “overweight” rating for the company in a research report on Thursday, February 6th. Mizuho lowered their price target on shares of Align Technology from $295.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Leerink Partners raised shares of Align Technology from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $235.00 to $280.00 in a report on Monday, January 6th. Finally, Wells Fargo & Company assumed coverage on shares of Align Technology in a research note on Friday, February 14th. They issued an “overweight” rating and a $255.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $262.64.

Align Technology Price Performance

NASDAQ ALGN opened at $165.62 on Monday. The company’s fifty day moving average is $176.25 and its two-hundred day moving average is $206.43. The firm has a market capitalization of $12.13 billion, a price-to-earnings ratio of 29.52, a P/E/G ratio of 2.24 and a beta of 1.73. Align Technology has a 52-week low of $141.74 and a 52-week high of $327.49.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALGN. Picton Mahoney Asset Management raised its stake in shares of Align Technology by 69.9% in the fourth quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Align Technology in the fourth quarter valued at approximately $31,000. Aster Capital Management DIFC Ltd bought a new position in Align Technology in the 4th quarter worth approximately $35,000. Private Trust Co. NA lifted its holdings in Align Technology by 113.4% during the 4th quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 93 shares in the last quarter. Finally, Orion Capital Management LLC bought a new position in Align Technology in the 4th quarter valued at $42,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.